Ashling Wahner

Frontline endocrine therapy plus entrectinib failed to decrease RCB to 0/1 in patients with invasive lobular breast carcinoma.

Neoadjuvant data from the ADAPTcycle trial confirmed the limited benefit of chemotherapy over endocrine therapy in high-risk HR-positive breast cancer.

The FDA approved frontline retifanlimab/chemotherapy for metastatic SCAC and retifanlimab monotherapy for metastatic SCAC with progression on chemotherapy.

Pembrolizumab/paclitaxel with or without bevacizumab improved PFS vs placebo/chemotherapy with or without bevacizumab in platinum-resistant ovarian cancer.

To prepare for the 2025 ASCO Annual Meeting, breast cancer experts share the abstracts and discussions they’re most excited to see at the meeting.

Rami Komrokji, MD, discusses the evolution of lower-risk MDS treatments that reflect novel classification systems and trials exploring novel therapies.

Belrestotug plus dostarlimab did not improve PFS vs dostarlimab monotherapy in PD-L1–high NSCLC, supporting the termination of belrestotug development.

THE001, a doxorubicin-encapsulating thermosensitive liposome therapy, has been granted FDA orphan drug designation for soft tissue sarcoma.

Amer Zeidan, MBBS, discusses evolutions in the myelodysplastic syndrome treatment paradigm and ongoing research seeking to improve treatment efficacy.

Nicole Lamanna, MD, discusses pirtobrutinib decision-making in the relapsed/refractory CLL setting and ongoing earlier-line research with the agent.

Evan T. Hall, MD, MPhil, discusses the limited potential for immunotherapy rechallenge in patients with RCC and challenges with later-line RCC management.

SCG101 T-cell therapy was safe and induced sustained HBV clearance and antitumor activity in patients with advanced HBV-related hepatocellular carcinoma.

Petros Grivas, MD, PhD, discusses data from CheckMate 274 and how emerging data from bladder cancer trials are shaping immunotherapy strategies in MIBC.

Petros Grivas, MD, PhD, discusses key findings from the NIAGARA trial and how these data support the use of perioperative durvalumab in MIBC management.

A meeting has been requested to address the FDA's refusal to file an sBLA for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive papillary NMIBC.

An sBLA seeking the approval of epcoritamab plus rituximab and lenalidomide for relapsed/refractory FL is planned to be submitted to the FDA.

Experts from across oncology specialties shared some of the most talked-about abstracts and discussions from the 2025 AACR Annual Meeting.

Anna C. Pavlick, BSN, MSc, DO, MBA, discusses data for RP1 plus nivolumab and the evolving treatment landscape in advanced melanoma.

Read a recap of the episodes of OncLive On Air that aired in April 2025.

Patients with myelofibrosis who initiated ruxolitinib within 2 years of diagnosis achieved higher spleen response rates vs those with delayed initiation.

Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.

Rene Y. McNall-Knapp, MD, discusses the symptom management associated with mirdametinib and MEK inhibition in NF1-associated PNs.

Heinz-Josef Lenz, MD, and Van Karlyle Morris, MD, discuss the significance of the FDA approval of nivolumab plus ipilimumab for MSI-H/dMMR mCRC.

Aiwu Ruth He, MD, PhD, discusses data from the CheckMate 9DW trial that supported the FDA approval of frontline nivolumab plus ipilimumab for advanced HCC.

Evan Y. Yu, MD, discusses the clinical evolution of radiopharmaceuticals for patients with mCRPC and how PSMA PET may evolve to monitor treatment response.

Douglas Flora, MD, FACCC, LSSBB, discusses the growing role of artificial intelligence tools in oncology practice.

Nerea Lopetegui-Lia, MD, discusses fertility preservation options for patients with TNBC and considerations for managing treatment-related toxicities.

Frontline T-DXd plus pertuzumab led to statistically significant and clinically meaningful PFS improvements vs THP in HER2+ metastatic breast cancer.

R. Lor Randall, MD, FACS, discusses the importance of orthopedic oncology consensus meetings and the need for agreement about certain surgical practices.

Nerea Lopetegui-Lia, MD, discusses ongoing trials investigating ADCs that are shaking up the metastatic triple-negative breast cancer setting.